IMRN - Immuron Limited
After hours:
Chart Events
Double Moving Average Crossover
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.9700 |
| Open | 1.9600 |
| Bid | 1.8000 x 1400 |
| Ask | 2.0500 x 1400 |
| Day's Range | 1.8550 - 1.9500 |
| 52 Week Range | 1.3900 - 3.2100 |
| Volume | |
| Avg. Volume | 360,350 |
| Market Cap | 10.896M |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
GlobeNewswireImmuron Initiates Recruitment of Travelan® Clinical Study
Highlights: Immuron receives approval from U.S. Army Medical Research and Development CommandRecruitment and screening of healthy volunteers for Travelan® Controlled Human Infection Model (CHIM) Clinical Trial is in progressClinical Trial to examine a dosing regimen for Travelan® more suited to the US military will commence shortlyTravelan® is known to protect against the onset of Travelers diarrhea (TD), the most common illness reported by travelersThis is one of three Phase 2 studies with FDA
- Newsfile
Immuron Limited Announces Participation in the LD Micro Invitational XIII
Melbourne, Australia--(Newsfile Corp. - May 16, 2023) - Immuron Limited (ASX: IMC) (NASDAQ: IMRN) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private 1:1 meetings. Immuron Limited is scheduled to present on June 6th at 02:00 PM PT. Steven Lydeamore, ...
BenzingaFDA Lifts Clinical Hold From Immuron's New Campylobacter ETEC Therapeutic Study
Immuron Limited (NASDAQ: IMRN) has announced that the U.S. Naval Medical Research Center (NMRC) has received FDA approval to proceed with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The FDA has removed a clinical hold on the Investigational New Drug (IND) application allowing the NMRC to proceed with its plans to evaluate the efficacy of the hyperimmune product to prevent infectious
- GlobeNewswire
Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation
Highlights: U.S. Food and Drug administration (FDA) remove clinical hold on New Campylobacter ETEC Therapeutic IND applicationUS Naval Medical Research Centre (NMRC) satisfactorily addressed all clinical hold issues identified by the FDAIND to evaluate the efficacy of new Campylobacter ETEC Therapeutic in two human Phase 2 clinical trials is now activeOne trial will focus on the ability of the hyperimmune product to prevent infectious diarrhoea caused by ETEC The second trial will focus on prote
- GlobeNewswire
Immuron CEO, Steven Lydeamore to present at Coffee Microcaps
MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide a copy of the presentation being made today in Melbourne at Coffee Microcaps Conference by our Chief Executive Officer, Steven Lydeamore. A copy of the presentation slide deck is available
- GlobeNewswire
Immuron Q3 FY23 Business Update Presentation
MELBOURNE, Australia, April 19, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide the Q3 FY23 Investor Presentation for the business update webinar to be held today at 11:00 am (AEST). The Investor Presentation includes the following material information (unaudited): W
- GlobeNewswire
Q3 FY23 Business Update Webinar Notification
MELBOURNE, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to advise it will provide a business update for the quarter ended 31 March 2023 (Q3 FY23). Investors are invited to join a live webcast and Q&A hosted by Immuron CEO Steven Lydeamore on Wednesday, 1
- GlobeNewswire
Immuron Q3 Sales reach 150% of 1H Sales
Highlights: Australian Q3 FY23 sales of A$577 k (201% of 1H sales)North American Q3 FY23 Travelan® sales of A$298 k (100% of 1H sales)Global Q3 YTD FY23 sales of A$1.46 M represent an increase of 239% compared with the corresponding period in FY22 of A$430 k MELBOURNE, Australia, April 06, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic pro
Simply Wall St.Immuron First Half 2023 Earnings: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)
Immuron ( ASX:IMC ) First Half 2023 Results Key Financial Results Net loss: AU$1.98m (loss widened by 9.2% from 1H...
- GlobeNewswire
Immuron CEO, Steven Lydeamore to host an investor webinar
MELBOURNE, Australia, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, invites investors to join a live webcast hosted by Steven Lydeamore, CEO of Immuron Limited. Tuesday, 28 February 2023 at 11:00am Australian Eastern Standard Time (AEDT). To register in advance for this webinar,
- GlobeNewswire
Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic
MELBOURNE, Australia, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, today announces that a response letter has been submitted to the US Food and Drug Administration (FDA). Immuron has previously reported feedback was received from the FDA following a review of the Investigation
- GlobeNewswire
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study157 participants successfully randomized into the Clinical StudyPlans in place to enrol in 1302 healthy volunteers in total Infectious diarrhea is the most common illness reported by travelers & military personnel MELBOURNE, Australia, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially
- GlobeNewswire
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease
MELBOURNE, Australia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that has been granted a European Patent for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease. Notification of the decision to g
- GlobeNewswire
Immuron Receives FDA Approval for Travelan IND Application
Highlights: Immuron receives U.S. Food and Drug administration (FDA) approval for Travelan Investigational New Drug (IND) application IND to evaluate the efficacy of a single dose of Travelan to prevent infectious diarrhea caused by ETEC is now activePlans in place to initiate a Human clinical trial in 60 healthy volunteers in the USAClinical Trial to examine a dosing regimen for Travelan more suited for use by the US militaryInfectious diarrhea is the most common illness reported by travelers M
- GlobeNewswire
Immuron Submits IND Application To FDA for Travelan
Highlights: Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA)Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the USAClinical Trial to examine a dosing regimen for Travelan more suited for use by the US militaryInfectious diarrhea is the most common illness reported by travelers MELBOURNE, Australia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated
- GlobeNewswire
Immuron completes strategic investment in leading gut health biotech Ateria Health
Highlights: Immuron has completed settlement of strategic investment in leading gut health biotech Ateria Health, in accordance with signed subscription and option agreement (announced 13 October 2022): Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of Ateria Health; Option for further investment of £1.47m, expiring on 31 July 2023 Ateria Health is a U.K. based biotech company that develops and distributes supplements for overall health, including products that
- GlobeNewswire
Immuron CEO, Steven Lydeamore to present at AusBioInvest
MELBOURNE, Australia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases; is pleased to provide investors with a copy of the presentation slide deck to be showcased at AusBioInvest 2022 in Perth, Australia on October 27, 2022, by our Chief Executive Officer, Steven Lydeamore. A copy
BenzingaImmuron Announces Strategic Investment In UK-Based Gut Health Company
Immuron Limited (NASDAQ: IMRN) signed a strategic investment and option agreement with Ateria Health Limited for an upfront cash investment of £1.48 million. The company has also announced a strategic investment of approximately £1.5 million (A$2.6 million) to acquire an initial 17.5% of Ateria Health. Potential adjustment to share percentage for Immuron dependent on Ateria's performance during its CY2023. Ateria Health Ltd is a U.K.-based health and wellness company that has developed a novel i
- GlobeNewswire
Immuron strategic investment in leading gut health biotech Ateria Health
Highlights: Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health: Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of Ateria Health; Option for further investment of £1.47m, expiring on 31 July 2023 Ateria Health is a U.K. based biotech company that develops and distributes supplements for overall health, including products that strengthen the gut microbiome. Ateria has developed and recently launched a ground-breaki
- GlobeNewswire
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
Highlights: Clinical Trial Master Service Agreement with US-based Pharmaron ExecutedInvestigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA)Plans in place to initiate a Controlled Human Infection Model (CHIM) clinical trial in 60 healthy volunteers in the USAClinical Trial to examine a dosing regimen for Travelan more suited for use by the US militaryInfectious diarrhea is the most common illness reported by travelers MELBOURNE, Australia, Oct. 04
BenzingaImmuron Pulls Plug On COVID-19 Treatment Hopeful, Citing Changing Landscape
Immuron Limited (NASDAQ: IMRN) has deprioritized SARS-CoV-2 research to focus on the clinical development of more advanced-stage therapeutic drug candidates. Immuron enters FY23 with a newly appointed CEO completing an assessment of the entire product portfolio, target markets, competitive advantage, and key growth drivers. Related: Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19. Considering research findings, the rapid evolution of the virus and changing treatment la
- GlobeNewswire
Immuron Update on IMM-124E SARS-CoV-2 Research
MELBOURNE, Australia, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; today announced that it has deprioritized SARS-CoV-2 research to focus on the clinical development of our more advanced stage therapeutic drug candidates. Immuron enters FY23 with a newly appointed CEO who is completing an assessment of the entire pr
BenzingaImmuron's IND Application For Bacterial Infection Candidate Placed On Clinical Hold
The U.S. Naval Medical Research Center (NMRC) has received FDA feedback related to Immuron Limited's (NASDAQ: IMRN) Investigational New Drug (IND) application for a new oral therapeutic targeting Campylobacter and ETEC. The agency has specified that the IND does not contain sufficient information to assess the risk to subjects in the proposed clinical studies. The IND has been placed on clinical hold until the FDA has received and reviewed a response from the NMRC justifying dosing, safety monit
- GlobeNewswire
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic
MELBOURNE, Australia, July 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today announced that the US Naval Medical Research Center (NMRC) has received feedback from the US Food and Drug Administration following a review of the Investigational New Drug (IND) application for a new oral therapeutic targeting Cam
- GlobeNewswire
Immuron North American Travelan® Sales up 494% and Global sales up 431%
Highlights: North American FY22 Travelan® sales increased by +494% to $0.6MGlobal sales increased by 431% to $0.9MAustralian FY22 sales increased by 318% to $0.3M MELBOURNE, Australia, July 11, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce the FY22 sales results o